The future of integrase inhibitors of HIV-1

Craigie, 2012, HIV DNA integration, Cold Spring Harbor Perspectives in Medicine, 2, a006890, 10.1101/cshperspect.a006890 Shun, 2007, LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration, Genes and Development, 21, 1767, 10.1101/gad.1565107 Ciuffi, 2005, A role for LEDGF/p75 in targeting HIV DNA integration, Nature Medicine, 11, 1287, 10.1038/nm1329 Lewinski, 2006, Retroviral DNA integration: viral and cellular determinants of target-site selection, PLoS Pathogens, 2, e60, 10.1371/journal.ppat.0020060 Engelman, 1992, Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro, Journal of Virology, 66, 6361, 10.1128/JVI.66.11.6361-6369.1992 Hare, 2010, Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance, Proceedings of the National Academy of Sciences of the United States of America, 107, 20057, 10.1073/pnas.1010246107 Kulkosky, 1992, Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases, Molecular and Cellular Biology, 12, 2331, 10.1128/MCB.12.5.2331 Faure, 2005, HIV-1 integrase crosslinked oligomers are active in vitro, Nucleic Acids Research, 33, 977, 10.1093/nar/gki241 Guiot, 2006, Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity, Journal of Biological Chemistry, 281, 22707, 10.1074/jbc.M602198200 Hazuda, 2000, Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells, Science, 287, 646, 10.1126/science.287.5453.646 Bera, 2009, Molecular interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration, Journal of Molecular Biology, 389, 183, 10.1016/j.jmb.2009.04.007 Kawasuji, 2006, A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors, Bioorganic and Medicinal Chemistry, 14, 8420, 10.1016/j.bmc.2006.08.043 Marchand, 2003, Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S), Molecular Pharmacology, 64, 600, 10.1124/mol.64.3.600 Blanco, 2011, HIV-1 integrase inhibitor resistance and its clinical implications, Journal of Infectious Diseases, 203, 1204, 10.1093/infdis/jir025 Grinsztejn, 2007, Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial, Lancet, 369, 1261, 10.1016/S0140-6736(07)60597-2 Summa, 2008, Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection, Journal of Medicinal Chemistry, 51, 5843, 10.1021/jm800245z Lennox, 2009, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, Lancet, 374, 796, 10.1016/S0140-6736(09)60918-1 Markowitz, 2007, Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study, Journal of Acquired Immune Deficiency Syndromes, 46, 125, 10.1097/QAI.0b013e318157131c Steigbigel, 2008, Raltegravir with optimized background therapy for resistant HIV-1 infection, New England Journal of Medicine, 359, 339, 10.1056/NEJMoa0708975 Steigbigel, 2010, Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials, Clinical Infectious Diseases, 50, 605, 10.1086/650002 Eron, 2010, Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials, Lancet, 375, 396, 10.1016/S0140-6736(09)62041-9 Sato, 2006, Novel HIV-1 integrase inhibitors derived from quinolone antibiotics, Journal of Medicinal Chemistry, 49, 1506, 10.1021/jm0600139 Wills, 2012, Elvitegravir: a once-daily inhibitor of HIV-1 integrase, Expert Opinion on Investigational Drugs, 21, 395, 10.1517/13543784.2012.658914 DeJesus, 2012, Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects showing efficacy, safety, and pharmacokinetics Sax, 2012, Elvitegravir/cobicistat/emtricitabine/tenofovir (quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects Min, 2010, Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers, Antimicrobial Agents and Chemotherapy, 54, 254, 10.1128/AAC.00842-09 van Lunzen, 2012, Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial, Lancet Infectious Diseases, 12, 111, 10.1016/S1473-3099(11)70290-0 Soriano, 2011, Dolutegravir (DTG, S/GSK1349572) treatment of HIV suppression at week 24 in the VIKING study Al-Mawsawi, 2008, Anti-infectives: clinical progress of HIV-1 integrase inhibitors, Expert Opinion on Emerging Drugs, 13, 213, 10.1517/14728214.13.2.213 Vacca, 2007, Discovery of MK-2048 – subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors Quashie, 2012, Novel therapeutic strategies targeting HIV integrase, BMC Medicine, 10, 34, 10.1186/1741-7015-10-34 Cooper, 2008, Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection, New England Journal of Medicine, 359, 355, 10.1056/NEJMoa0708978 Malet, 2008, Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro, Antimicrobial Agents and Chemotherapy, 52, 1351, 10.1128/AAC.01228-07 Shimura, 2008, Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137), Journal of Virology, 82, 764, 10.1128/JVI.01534-07 Croxtall, 2009, Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients, Drugs, 69, 1059, 10.2165/00003495-200969080-00007 Delelis, 2010, Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo, Antimicrobial Agents and Chemotherapy, 54, 491, 10.1128/AAC.01075-09 Sichtig, 2009, Evolution of raltegravir resistance during therapy, Journal of Antimicrobial Chemotherapy, 64, 25, 10.1093/jac/dkp153 Goethals, 2008, Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors, Journal of Virology, 82, 10366, 10.1128/JVI.00470-08 Kobayashi, 2011, In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor, Antimicrobial Agents and Chemotherapy, 55, 813, 10.1128/AAC.01209-10 Quashie, 2012, Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir, Journal of Virology, 86, 2696, 10.1128/JVI.06591-11 Bar-Magen, 2010, Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor, Journal of Virology, 84, 9210, 10.1128/JVI.01164-10 Lenz, 2011, S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges, Expert Opinion on Investigational Drugs, 20, 537, 10.1517/13543784.2011.562189 Malet, 2011, The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype, Journal of Antimicrobial Chemotherapy, 66, 2827, 10.1093/jac/dkr389 Margot, 2012, In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4, Antiviral Research, 93, 288, 10.1016/j.antiviral.2011.12.008 Reuman, 2010, Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector, Antimicrobial Agents and Chemotherapy, 54, 934, 10.1128/AAC.01345-09 Seki, 2012, High barrier to resistance for dolutegravir (DTG, S/GSK1349572) against raltegravir-resistant Y143 mutants: an in vitro passage study Van Wesenbeeck, 2011, Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates, Antimicrobial Agents and Chemotherapy, 55, 321, 10.1128/AAC.01733-09 Christ, 2010, Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication, Nature Chemical Biology, 6, 442, 10.1038/nchembio.370 Christ, 2012, Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization, Antimicrobial Agents and Chemotherapy, 56, 4365, 10.1128/AAC.00717-12 Christ, 2012, Preclinical evaluation of HIV replication inhibitors that target the HIV integrase-LEDGF/p75 interaction